In recent years, the occurrence of cancer during pregnancy has emerged as a significant and complex medical challenge, owing to its increasing incidence in reproductive-age individuals. New data suggest that approximately one in every 1,000 pregnancies in the United States is complicated by cancer, a statistic that underscores the urgent need for evidence-based clinical guidelines tailored to this unique patient population. The Society for Maternal-Fetal Medicine (SMFM) has now stepped into this critical gap by issuing its inaugural comprehensive guidance aimed at healthcare professionals managing cancer in pregnant patients, providing a roadmap that balances oncologic efficacy with maternal and fetal health considerations.
The rising maternal age in many populations may partially explain the increased frequency of cancer diagnoses during pregnancy, but this is only part of the story. Enhanced cancer screening protocols and widespread use of advanced diagnostic technologies, including cell-free DNA (cfDNA) prenatal genetic screening, have significantly contributed to the early and sometimes unexpected detection of malignancies in pregnant individuals. This has led to an uptick not only in diagnoses of early-stage cancers but also in identifying metastatic disease that might otherwise have gone unnoticed until later stages.
Historically, managing cancer during pregnancy has been fraught with uncertainty. The dearth of robust clinical research and fear of teratogenic effects from cancer therapies often led to delayed or withheld treatment, with clinicians erring on the side of caution to protect the developing fetus. However, recent advances in oncologic therapies and a deeper understanding of fetal tolerance to various treatments have transformed this paradigm. Today, emerging evidence suggests that many pregnant patients can safely undergo surgery, chemotherapy, and even radiation under carefully controlled circumstances, allowing clinicians to offer treatments that do not compromise pregnancy outcomes.
The newly published SMFM guidelines synthesize the multidisciplinary consensus and scientific literature into practical recommendations. These guidelines address commonly diagnosed malignancies in pregnancy, including breast cancer, cervical cancer, colorectal cancer, thyroid neoplasms, Hodgkin and non-Hodgkin lymphomas, leukemia, melanoma, and ovarian cancer. Each cancer type is examined in the context of disease biology, stage at presentation, and timing relative to gestational age, permitting nuanced management strategies that consider both oncologic control and fetal safety.
Imaging diagnostics have evolved to accommodate pregnancy-specific risks, with ultrasonography and noncontrast magnetic resonance imaging (MRI) now recommended as first-line tools to evaluate suspected malignancies. Such modalities circumvent ionizing radiation exposure, which poses teratogenic risks, thereby enabling clinicians to obtain crucial diagnostic information while preserving fetal integrity. The guidelines underscore that delaying surgical intervention due to pregnancy is unwarranted; surgical procedures can and should proceed when indicated, irrespective of gestational stage, to optimize maternal prognosis.
Thromboprophylaxis emerges as a critical component in the management of pregnant cancer patients due to the recognized hypercoagulable state induced by malignancy and pregnancy alike. The SMFM advises thromboprophylaxis for all patients with active hematologic or gynecologic cancers and recommends individualized assessment for those with other cancer types. Preventing thromboembolic events is paramount, as these complications pose significant risks to both maternal and fetal health, with morbidity and mortality implications.
Chemotherapeutic regimens, once considered contraindicated during pregnancy, have found a place in treatment protocols post-first trimester. Most cytotoxic agents appear to be safer when initiated after 12 weeks’ gestation, coinciding with the conclusion of organogenesis and a reduced risk of major congenital anomalies. The guidelines emphasize individualized consultations with oncology specialists to weigh the risks and benefits of treatment timing, especially when diagnosis occurs in the first trimester and pregnancy continuation is desired by the patient.
The fetal monitoring paradigm has adapted to the complexities introduced by maternal cancer and its treatment. Serial fetal growth assessments every three to four weeks are recommended irrespective of therapeutic approach, recognizing that malignancy and oncologic interventions can adversely affect placental function and fetal development. Such surveillance facilitates early detection of growth restriction or other complications, permitting timely intervention and optimizing perinatal outcomes.
Cancer during pregnancy introduces intricate clinical dilemmas that necessitate a multidisciplinary, patient-centered approach. The guidelines advocate assembling dedicated care teams, including maternal-fetal medicine specialists, oncologists, surgeons, radiologists, and neonatologists, to tailor treatment plans that respect the patient’s values, pregnancy goals, and clinical realities. This team-based approach ensures balanced decision-making that supports both effective cancer management and fetal welfare.
An important aspect of these guidelines is their recognition of the expanding role of prenatal genetic screenings like cfDNA not only in fetal assessment but also as serendipitous cancer detection tools. Incidental findings of abnormal cfDNA results have unmasked occult maternal malignancies, prompting further investigation and early intervention. This phenomenon presents both clinical opportunities and challenges, as unexpected cancer diagnoses during pregnancy require rapid yet thoughtful management strategies.
While the SMFM guidelines represent a milestone in codifying cancer care during pregnancy, they also highlight the ongoing need for research into long-term maternal and infant outcomes following in utero exposure to chemotherapy, radiation, and surgical interventions. Available data have begun to allay earlier fears by documenting reassuring developmental outcomes, but comprehensive, longitudinal studies remain imperative to solidify safety profiles and optimize treatment protocols.
The guidelines underscore that withholding cancer treatment solely based on pregnancy status is unjustified. Ensuring equitable access to the full spectrum of reproductive and oncologic options, from fertility preservation techniques to pregnancy continuation or termination discussions, is essential. These options must be presented without bias, allowing patients to make informed decisions supported by their healthcare team.
Cancer in pregnancy is no longer an insurmountable barrier to therapy. Through the lens of technological advances, multidisciplinary collaboration, and evidence-based protocols, clinicians can now offer personalized and effective treatment strategies that preserve maternal health without compromising fetal outcomes. The SMFM Consult Series #76 sets a new clinical standard, equipping providers worldwide with the tools and knowledge necessary to navigate this complex intersection of oncology and obstetrics.
As cancer incidence continues to climb among younger populations, these guidelines will be pivotal in shaping future research agendas, clinical training, and patient advocacy. By addressing the nuanced challenges posed by cancer in pregnancy, the medical community moves closer to a future where every pregnant patient receives optimal, compassionate, and scientifically grounded care.
Subject of Research: Diagnosis and management of cancer during pregnancy
Article Title: SMFM’s First Evidence-Based Clinical Guidance on Cancer in Pregnancy
News Publication Date: Not specified in the provided content
Web References:
– https://obgyn.onlinelibrary.wiley.com/doi/10.1002/pmf2.70221
References: Not explicitly listed in the provided content
Image Credits: Not specified
Keywords: cancer in pregnancy, maternal-fetal medicine, oncology, chemotherapy during pregnancy, cancer diagnosis, prenatal imaging, thromboprophylaxis, multidisciplinary care, fetal growth surveillance, cell-free DNA screening
